ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03292848, Trial to assess the pharmacokinetics, safety, tolerability of oral brexpiprazole in children (6 to <13 years old) with central nervous system disorders; 2017 Oct 10 [cited 2022 Mar 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03292848?term=brexpiprazole&age=0&draw=2&rank=3Google Scholar

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02411695, Study to assess the safety, tolerability and pharmacokinetics of oral brexpiprazole (OPC- 34712) in adolescents with schizophrenia; 2015 Mar [cited 2022 Mar 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT02411695?term=brexpiprazole&age=0&draw=2&rank=6Google Scholar

Koch, MT, Carlson, HE, Kazimi, MM, Correll, CU. Antipsychotic-related prolactin levels and sexual dysfunction in mentally ill youth: a 3-month cohort-study. J Am Acad Child Adolesc Psychiatry 2023 ;62(9):1021–50.CrossRefGoogle ScholarPubMed

Miklowitz, DJ, Schneck, CD, Walshaw, PD et al. Effects of family-focused therapy vs enhanced usual care for symptomatic youths at high risk for bipolar disorder: a randomized clinical trial. JAMA Psychiatry 2020 1;77(5):455–63.CrossRefGoogle ScholarPubMed

Pillay, J, Boylan, K, Carrey, N et al. First- and Second-Generation Antipsychotics in Children and Young Adults: Systematic Review Update [Internet]. Rockville, MD: Agency for Healthcare Research and Quality (US); 2017 Mar. Report No.: 17-EHC001-EF. AHRQ Comparative Effectiveness Reviews.Google Scholar